COVID-19 and Antihistamines: A Study on Hospital Admissions
Author Information
Author(s): Puigdellívol-Sánchez Anna, Juanes-González Marta, Calderón-Valdiviezo Ana, Losa-Puig Helena, Valls-Foix Roger, González-Salvador Marta, Lozano-Paz Celia, Vidal-Alaball Josep
Primary Institution: Consorci Sanitari de Terrassa
Hypothesis
Do patients receiving chronic antihistamines show better clinical outcomes during COVID-19?
Conclusion
Patients with chronic antihistamine prescriptions showed reduced hospital admission and mortality rates during COVID-19.
Supporting Evidence
- Patients treated with antihistamines had no deaths in the study.
- Hospital admission rates were significantly lower in patients taking antihistamines.
- Previous studies indicated high mortality rates in nursing homes without antihistamine treatment.
Takeaway
This study found that people taking antihistamines regularly had fewer hospital visits and deaths from COVID-19, suggesting these medicines might help.
Methodology
The study analyzed anonymized data of COVID-19 hospital admissions and cases, comparing outcomes based on antihistamine use and chronic treatments.
Potential Biases
Selection bias may have occurred due to differences in testing and treatment availability across groups.
Limitations
The study was limited by the lack of precise quantification of cases in the first wave and potential biases in vaccination rates.
Participant Demographics
The study included a diverse population from the North Metropolitan Barcelona Health Region, with varying socioeconomic backgrounds.
Statistical Information
P-Value
p < 0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website